Insmed INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Feb 2026

INSM

10-K: Insmed Reports Strong Revenue Growth, Expands Pipeline

Insmed Incorporated reported significant revenue growth in 2025 driven by the launch of BRINSUPRI and international ARIKAYCE sales, alongside substantial investments in its clinical pipeline and R&D.

NASDAQ

20 Feb 2025

INSM

Insmed INC

10-K: Insmed's 10-K Filing Reveals Strategic Focus on Growth and Pipeline Advancement

Insmed's 2024 10-K filing highlights the company's commitment to delivering therapies for serious diseases, advancing its pipeline, and expanding its commercial reach.

NASDAQ

22 Feb 2024

INSM

Insmed INC

10-K: Insmed's 2023 10-K Filing: A Deep Dive into Financials, Pipeline, and Future Outlook

Insmed's 2023 10-K filing details the company's financial performance, clinical pipeline progress, and strategic priorities, highlighting both achievements and challenges.